Non-esterified fatty acid levels correlate with peripheral artery disease risk

 

Non-esterified fatty acids (NEFAs) are free fatty acids that circulate in the bloodstream and play a key role in energy metabolism. Recent research has indicated that elevated levels of NEFAs are associated with an increased risk of peripheral artery disease (PAD), a condition characterized by the buildup of plaque in the arteries that supply blood to the legs and feet.

PAD is a common and serious condition that affects millions of people worldwide and is associated with a significant risk of heart attack, stroke, and death. Despite its prevalence, PAD often goes undiagnosed, as many individuals experience few or no symptoms.

Studies have shown that individuals with elevated levels of NEFAs have a higher risk of developing PAD compared to those with normal NEFA levels. This relationship is thought to be due to the fact that NEFAs are involved in the regulation of insulin resistance and inflammation, two key risk factors for PAD.

Elevated levels of NEFAs can lead to insulin resistance, a condition in which the body's cells become resistant to the effects of insulin, leading to increased glucose levels in the bloodstream. Insulin resistance is a major risk factor for PAD, as it promotes the accumulation of plaque in the arteries. Additionally, elevated NEFAs are associated with increased inflammation, which can further contribute to the development of PAD.

Several studies have found that individuals with elevated levels of NEFAs also have a higher risk of cardiovascular disease, including PAD. For example, a large population-based study found that individuals with elevated levels of NEFAs had a 68% increased risk of PAD compared to those with normal NEFA levels. Other studies have reported similar findings, suggesting that elevated NEFA levels are a strong predictor of PAD risk.

The mechanisms by which elevated NEFAs contribute to PAD risk are not fully understood, but they are thought to involve the regulation of insulin resistance and inflammation. In addition, elevated NEFAs may also contribute to oxidative stress, a condition in which the body produces too many harmful reactive oxygen species. Oxidative stress is associated with the development of PAD, as it can damage the walls of the arteries and contribute to the formation of plaque.

There is evidence that lifestyle modifications can help reduce NEFA levels and improve insulin sensitivity. For example, exercise and weight loss have been shown to reduce NEFA levels and improve insulin sensitivity, potentially reducing the risk of PAD. Additionally, some medications, such as statins, have been shown to reduce NEFA levels and improve insulin sensitivity, potentially reducing the risk of PAD.

In conclusion, elevated levels of NEFAs are associated with an increased risk of peripheral artery disease. This relationship is thought to be due to the regulation of insulin resistance and inflammation, two key risk factors for PAD. Future research is needed to fully understand the mechanisms underlying the relationship between NEFAs and PAD and to develop effective interventions to reduce the risk of PAD in individuals with elevated NEFA levels.